Matinas BioPharma Holdings (MTNB) Net Income (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Net Income of -$1.9 million for Q1 2026, up 1.07% year-over-year from -$1.9 million in Q1 2025, and down 13.55% quarter-over-quarter from -$1.7 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Net Income (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Net Income for 13 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income rose 1.07% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$7.6 million (up 70.14% YoY), while the FY2025 annual figure was -$10.3 million, up 57.34% from the prior year.
- Net Income fell to -$1.9 million in Q1 2026 per MTNB's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Net Income topped out at -$1.7 million in Q4 2025 and bottomed at -$39.9 million in Q4 2022.
- Historically, Net Income has averaged -$8.1 million across 5 years, with a median of -$6.8 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income sank 107.67% — and 2023, when it jumped 85.23%.
- Matinas BioPharma Holdings' Net Income stood at -$39.9 million in 2022, then surged by 85.23% to -$5.9 million in 2023, then tumbled by 44.36% to -$8.5 million in 2024, then soared by 79.86% to -$1.7 million in 2025, then decreased by 13.55% to -$1.9 million in 2026.
- Business Quant data shows MTNB's Net Income at -$1.9 million in Q1 2026, -$1.7 million in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 81.49 Mn |
| 10 | Matinas BioPharma Holdings | 1.27 Mn | 454,222.76 | - | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.56 Mn |
| Mar 31, 2026 | -1.94 Mn |
| Dec 31, 2025 | -1.71 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | -2.11 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -8.50 Mn |
| Sep 30, 2024 | -5.33 Mn |
| Jun 30, 2024 | -9.72 Mn |
| Mar 31, 2024 | -6.85 Mn |
| Dec 31, 2023 | -5.89 Mn |
| Sep 30, 2023 | -7.17 Mn |
| Jun 30, 2023 | -7.20 Mn |
| Mar 31, 2023 | -6.66 Mn |
| Dec 31, 2022 | -39.87 Mn |
| Sep 30, 2022 | -10.95 Mn |
| Jun 30, 2022 | -11.42 Mn |
| Mar 31, 2022 | -8.48 Mn |
| Dec 31, 2021 | -37.74 Mn |
| Sep 30, 2021 | -13.02 Mn |